{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:01:50Z","timestamp":1790226110649,"version":"4.1.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hanmi Pharmaceutical Co.,Ltd","award":["HM-IIT-NAX-001"],"award-info":[{"award-number":["HM-IIT-NAX-001"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0226184","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T13:33:53Z","timestamp":1580132033000},"page":"e0226184","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["A comparative study of the efficacy of NAXOZOL compared to celecoxib in patients with osteoarthritis"],"prefix":"10.1371","volume":"15","author":[{"given":"Moon Soo","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Nam","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo-Suk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Joong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahnghoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5165-1159","authenticated-orcid":true,"given":"Seong-Hwan","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,1,27]]},"reference":[{"issue":"5","key":"pone.0226184.ref001","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1586\/ecp.11.36","article-title":"Managing the adverse effects of nonsteroidal anti-inflammatory drugs","volume":"4","author":"P Patrignani","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"pone.0226184.ref002","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00042737-199904000-00003","article-title":"Toxicity of NSAIDs in the stomach and duodenum","volume":"11","author":"A Lanas","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"19","key":"pone.0226184.ref003","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/archinte.160.19.2998","article-title":"Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis","volume":"160","author":"DJ Watson","year":"2000","journal-title":"Arch Intern Med"},{"issue":"3","key":"pone.0226184.ref004","doi-asserted-by":"crossref","first-page":"R644","DOI":"10.1186\/ar1704","article-title":"Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports","volume":"7","author":"RA Moore","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"pone.0226184.ref005","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1365-2036.2006.03210.x","article-title":"Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs","volume":"25","author":"CJ Hawkey","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"pone.0226184.ref006","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1572-0241.2006.00499.x","article-title":"Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors","volume":"101","author":"JM Scheiman","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"pone.0226184.ref007","first-page":"728","article-title":"Guidelines for prevention of NSAID-related ulcer complications","volume":"104","author":"FL Lanza","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"pone.0226184.ref008","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2036.2010.04361.x","article-title":"Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen\/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers","volume":"32","author":"P Miner","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"pone.0226184.ref009","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3109\/07853890.2011.625971","article-title":"A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials","volume":"43","author":"BL Cryer","year":"2011","journal-title":"Ann Med"},{"key":"pone.0226184.ref010","first-page":"1","article-title":"Efficacy and tolerability of naproxen\/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses","volume":"5","author":"C Datto","year":"2013","journal-title":"Open Access Rheumatol"},{"issue":"3","key":"pone.0226184.ref011","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2036.2010.04378.x","article-title":"Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone","volume":"32","author":"JL Goldstein","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"pone.0226184.ref012","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1185\/03007995.2011.555756","article-title":"Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers","volume":"27","author":"MB Sostek","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"pone.0226184.ref013","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1517\/14656566.2014.911841","article-title":"Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium)","volume":"15","author":"PJ Parekh","year":"2014","journal-title":"Expert Opin Pharmacother"},{"issue":"1447","key":"pone.0226184.ref014","first-page":"64","article-title":"In brief: Esomeprazole strontium","volume":"56","year":"2014","journal-title":"Med Lett Drugs Ther"},{"key":"pone.0226184.ref015","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.2147\/DDDT.S86725","article-title":"Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO(R) (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers","volume":"9","author":"Y Choi","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"pone.0226184.ref016","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1056\/NEJMoa052639","article-title":"A placebo-controlled trial of itopride in functional dyspepsia","volume":"354","author":"G Holtmann","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0226184.ref017","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/j.1572-0241.2005.40701.x","article-title":"Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis","volume":"100","author":"L Rabeneck","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"pone.0226184.ref018","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/ard.2009.113100","article-title":"EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis","volume":"69","author":"W Zhang","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"pone.0226184.ref019","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1046\/j.1365-2036.1998.00404.x","article-title":"The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsia","volume":"12","author":"P Moayyedi","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"pone.0226184.ref020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01535722","article-title":"GSRS\u2014a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease","volume":"33","author":"J Svedlund","year":"1988","journal-title":"Dig Dis Sci"},{"issue":"7","key":"pone.0226184.ref021","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1063-4584(03)00082-7","article-title":"Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement","volume":"11","author":"JA Bolognese","year":"2003","journal-title":"Osteoarthritis Cartilage"},{"key":"pone.0226184.ref022","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","author":"Group TE","year":"1990","journal-title":"Health Policy"},{"issue":"5","key":"pone.0226184.ref023","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1572-0241.2005.41465.x","article-title":"Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors","volume":"100","author":"C Hawkey","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"pone.0226184.ref024","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1111\/j.1572-0241.2001.03932.x","article-title":"Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments","volume":"96","author":"NJ Talley","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"20","key":"pone.0226184.ref025","doi-asserted-by":"crossref","first-page":"e3585","DOI":"10.1097\/MD.0000000000003585","article-title":"Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials","volume":"95","author":"C Xu","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"pone.0226184.ref026","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.pmr.2005.12.012","article-title":"Nonsteroidal anti-inflammatory drugs","volume":"17","author":"CE Dugowson","year":"2006","journal-title":"Phys Med Rehabil Clin N Am"},{"issue":"1","key":"pone.0226184.ref027","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jcpt.12484","article-title":"Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis","volume":"42","author":"BR Gunter","year":"2017","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"pone.0226184.ref028","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","article-title":"Pharmacology of proton pump inhibitors","volume":"10","author":"JM Shin","year":"2008","journal-title":"Curr Gastroenterol Rep"},{"key":"pone.0226184.ref029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/DHPS.S7329","article-title":"Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease","volume":"3","author":"DN Roberts","year":"2011","journal-title":"Drug Healthc Patient Saf"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0226184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T13:34:13Z","timestamp":1580132053000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0226184"}},"subtitle":[],"editor":[{"given":"Cristina","family":"Vassalle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,27]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0226184","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,27]]}}}